Oruka Therapeutics Inc. (ORKA)
10.07
-0.43 (-4.10%)
At close: Apr 25, 2025, 3:59 PM
10.09
0.20%
After-hours: Apr 25, 2025, 04:05 PM EDT
Company Description
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications.
Its pipeline includes ORKA-001 and ORKA-002.
The company is headquartered in Menlo Park, CA.
Oruka Therapeutics Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Dr. Lawrence Otto Klein Ph.D. |
Contact Details
Address: 221 Crescent Street Building 23, Suite 105 Waltham, Massachusetts United States | |
| Website | http://www.orukatx.com |
Stock Details
| Ticker Symbol | ORKA |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 687604108 |
| ISIN Number | US6876041087 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Otto Klein Ph.D. | President, Chief Executive Officer & Director |
| Alan Lada | Vice President of Investor Relations |
| Christopher Finch | Vice President of Corporate Development & Strategy |
| Dr. Joana Goncalves M.D. | Chief Medical Officer |
| Dr. Joe Senn Ph.D. | Senior Vice President of Nonclinical Research & Development |
| Dr. Rajiv Panwar | Vice President and Head of Chemistry, Manufacturing & Controls |
| Laura Sandler | Senior Vice President of Operations & Boston Site Head |
| Paul T. Quinlan | General Counsel & Secretary |